Article: Pluristem Certified as a Good Manufacturing Practices (GMP) Site for the Manufacture of PLX cells for its Clinical Trials.

NEW YORK -- Pluristem Therapeutics Inc. (NASDAQ:PSTI); (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of degenerative, ischemic and autoimmune indications, today announced that the Company has received certification that its manufacturing facility in Haifa, Israel has been approved as a Good Manufacturing Practices (GMP) standard site for the purpose of manufacturing PLX cells which will be shipped to the EU for use in the Company's upcoming clinical trials. Pluristem was awarded this certification by Biotec Distribution Wales, Ltd., the designee of the Paul Ehrlich Institute, ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!